On April 5, 2017, José Baselga, M.D., Ph.D., informed Infinity Pharmaceuticals, Inc. of his decision to retire from Board of Directors effective at the end of his current term, which expires on the date of 2017 Annual Meeting of Stockholders (the ‘Annual Meeting’). Accordingly, Dr. Baselga will not stand for re-election to Board at 2017 Annual Meeting. On April 5, 2017, the company’s Board, based on the recommendation of the Nominating and Governance Committee of Board (the ‘Governance Committee’), elected Michael G. Kauffman, M.D., Ph.D., as an independent director. Additionally, the company’s Board, based on the recommendation of the Governance Committee, appointed Dr. Kauffman to the Governance Committee and the Research and Development Committee of Board. His term began on April 5, 2017, and will expire at 2017 annual meeting of stockholders or his earlier death, resignation, or removal.